/Free Psa Antibodies As Diagnostics, Prognostics And Therapeutics For Prostate Cancer
Abstract

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Full Text

What is claimed is:

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.
Timeline
Filed
06/12/2026
Published
10/01/2026
Granted
Not Available
IPC Codes(3)
A61K 51/10:Antibodies or immunoglobulins; Fragments thereof
A61B 5/00:Measuring for diagnostic purposes (radiation diagnosis A61B 6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B 8/00); Identification of persons
G01N 33/57555:of the prostate